Please login to the form below

Not currently logged in
Email:
Password:

Pfizer’s Elizabeth Barrett joins Novartis as its oncology head

She succeeds Bruno Strigini who retires

Elizabeth BarrettNovartis has appointed Elizabeth Barrett to head up its oncology franchise based at the group’s headquarters in Switzerland.

Barrett, who succeeds Bruno Strigini, has held numerous leadership positions in the pharmaceutical industry as well as in the commercial sector.

She most recently served Pfizer, leading its oncology business but has held several roles with the pharma giant including president, Europe, president North America, speciality care and US president of oncology.

She said: “I feel honoured to join Novartis. It is key to me to contribute to transformative advancements in oncology, and to serve in a highly impactful leadership role to this end.”

Prior to her time with Pfizer, Barrett held roles with Cephalon and Johnson & Johnson.

Vas Narasimhan, chief executive officer at Novartis, said: “Liz is a highly accomplished and recognised oncology and people leader with an impressive record of building successful business organisations in the US.

“She has been instrumental in creating new commercial models, driving innovation in close partnership with research and development and leveraging business development opportunities.

“Her long-time commercial pharma industry experience, marketing skills and perspectives make Liz a great fit to further develop our oncology business.”

12th January 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...